Skip to main content
. 2018 Feb 27;9(1):e00008-18. doi: 10.1128/mBio.00008-18

TABLE 1 .

Binding and neutralization of inhibitory anti-JEV MAbs

Mab Isotypea Domaina Cross-reactivitya FRNT50 (ng/ml)b
GI
 GII, Bennett GIII
 GIV, JKT 7887
2372/79 MAR 859 Nakayama SA14 SA14-14-2
Mouse
    JEV-27 IgG2c DIII N 4,830 4,053 3,846 2,332 1,441 1,779 2,433
    JEV-31 IgG2c DIII W 365 272 241 223 94 84 211
    JEV-106 IgG2c DIII N 449 500 548 334 147 199 270
    JEV-117 IgG2c N W >10,000 >10,000 >10,000 >10,000 >10,000 11 >10,000
    JEV-128 IgG2c DIII N 1,629 561 276 267 189 102 555
    JEV-131 IgG2c DIII N 509 336 263 409 207 95 815
    JEV-143 IgG2c DIII Z 435 405 358 346 368 379 818
    JEV-169 IgG2c DI N 69 80 88 112 148 49 315
 
Human
    hJEV-11 hIgG1, κ DIII W 5,445 1,509 4,116 >10,000 4,528 2,226 >10,000
    hJEV-69 hIgG1, κ DIII N 1,102 335 524 2,444 475 211 3,111
    hJEV-75 hIgG1, λ N N 457 228 388 294 414 9 >10,000
    hJEV-80 hIgG1, λ DIII W 3,371 1,117 1,036 >10,000 857 1,007 7,733
a

Immunoglobulin isotype, domain specificity, and cross-reactivity to WNV (W) and ZIKV (Z) were determined by ELISA. “N” indicates no binding to either WNV (W) or ZIKV (Z) recombinant E protein or JEV E protein domains.

b

Purified MAb was incubated with 102 FFU of the indicated JEV strain of genotypes GI to GIV for 1 h at 37°C. Fifty percent FRNT (FRNT50) values were determined by nonlinear regression. Results are the average from three independent experiments performed in triplicate.